9 hours Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy? The Motley Fool
The thrust of the company’s long-term strategy is becoming clearer.
The thrust of the company’s long-term strategy is becoming clearer.